Stathmin Serine 16 Phosphorylation Is a Key Regulator of Cell Cycle Progression Without Activating Metastatic Behavior
Preprint
- 30 May 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background: Treatment of metastatic cancer remains a challenge, because cancer cells acquire resistance even to the most contemporary therapies. This study analyzed the role of the phosphoprotein Stathmin 1 (STMN1) in regulating cancer cell growth and metastatic potential.Methods: Public datasets with metastatic castration-resistant prostate cancer (mCRPC) and breast cancer (BC) were analyzed to determine the interrelationship between STMN1, hepatocyte growth factor (HGF), and MET proto-oncogene (MET) expression, overall survival, and response to chemotherapy. Site-directed mutagenesis, cell cycle analysis, proliferation, migration and invasion assays determined the impact of STMN1 phosphorylation on proliferation and metastatic potential. Results: Increased STMN1 associates with HGF and MET gene expression in mCRPC, and taxane chemotherapy further increases HGF expression. STMN1 and HGF are highest, and overall survival is poorest in mCRPC to liver compared to other sites, implying the metastatic site influences their expression levels and potentially pattern of metastatic spread. Increased STMN1 and MET also predict taxane responsiveness in BC patients. Analysis of STMN1 serine (S)16, 25, 38, and 63 determined total (t) STMN1 and STMN1 S16 phosphorylation (pSTMN1S16) are co-regulated by HGF/MET during cell cycle progression, pSTMN1S16 alone can promote cell proliferation, and pSTMN1S16 shortens the cell cycle similar to HGF treatment, while STMN1S16 dephosphorylation lengthens the cell cycle to arrest cell growth in G2/M, similar to HGF plus the MET inhibitor AMG337. Importantly, STMN1S16 does not promote metastasis. Conclusion: Selectively inhibiting STMN1S16 phosphorylation may provide an alternative strategy for inhibiting MET-mediated cell growth to eliminate metastatic cancer cells and inhibit further metastasis.Keywords
All Related Versions
- Version 1, 2025-05-30, Preprints
- Published version: Cancers, 17 (14), 2322.
This publication has 82 references indexed in Scilit:
- Stathmin 1 expression in neuroendocrine and proliferating prostate cancerDiscover Oncology, 2025
- Synchronization of Cultured Cells to G1, S, G2, and M Phases by Double Thymidine Block2022
- ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti‐HER2 therapy using transcriptomic data of 3,104 breast cancer patientsInternational Journal of Cancer, 2019
- Higher order genomic organization and regulatory compartmentalization for cell cycle control at the G1/S‐phase transitionJournal of Cellular Physiology, 2018
- Cell Cycle Synchronization of HeLa Cells to Assay EGFR Pathway Activation2017
- Liver protects metastatic prostate cancer from induced death by activating E‐cadherin signalingHepatology, 2016
- Distribution of metastatic sites in patients with prostate cancer: A population‐based analysisThe Prostate, 2013
- MET and VEGF: synergistic targets in castration-resistant prostate cancerClinical and Translational Oncology, 2011
- Stathmin1 overexpression associated with polyploidy, tumor‐cell invasion, early recurrence, and poor prognosis in human hepatomaMolecular Carcinogenesis, 2010
- Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesisHepatology, 2007